{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T09:43:31Z","timestamp":1766828611116,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.clbc.2017.03.004","type":"journal-article","created":{"date-parts":[[2017,3,9]],"date-time":"2017-03-09T02:18:01Z","timestamp":1489025881000},"page":"433-440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Nab-Paclitaxel in Advanced HER2-negative Breast Cancer Patients: Efficacy and Safety Beyond Clinical Trials"],"prefix":"10.1016","volume":"17","author":[{"given":"Antonio","family":"Bernardo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Pedersini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Rota Caremoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Rita","family":"Gambaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8674-7062","authenticated-orcid":false,"given":"Antonella","family":"Ferzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9896-9896","authenticated-orcid":false,"given":"Francesca","family":"Riva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7648-2806","authenticated-orcid":false,"given":"Donatella","family":"Grasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Danova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiliana","family":"Tarenzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valter","family":"Torri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina E.","family":"Cazzaniga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2017.03.004_bib1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/BF02951422","article-title":"Taxanes in breast cancer: an update","volume":"9","author":"Conlin","year":"2007","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.clbc.2017.03.004_bib2","first-page":"66","article-title":"Taxanes in the first-line chemotherapy of metastatic breast cancer: review","volume":"25","author":"Friedrich","year":"2004","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.clbc.2017.03.004_bib3","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa0707056","article-title":"Weekly paclitaxel in the adjuvant treatment of breast cancer","volume":"358","author":"Sparano","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2017.03.004_bib4","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.2147\/DDDT.S86105","article-title":"The role of taxanes in triple-negative breast cancer: literature review","volume":"9","author":"Mustacchi","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clbc.2017.03.004_bib5","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2017.03.004_bib6","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1200\/JCO.2008.18.5397","article-title":"Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer","volume":"27","author":"Gradishar","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2017.03.004_bib7","first-page":"3407","article-title":"Nab-paclitaxel monotherapy as a treatment of patients with metastatic breast cancer in routine clinical practice","volume":"33","author":"Aigner","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clbc.2017.03.004_bib8","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1200\/JCO.2007.13.0344","article-title":"Disease control rate at 8 weeks predicts clinical benefit in advanced non\u2013small-cell lung cancer: results from southwest oncology group randomized trials","volume":"26","author":"Lara","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2017.03.004_bib9","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.2552","article-title":"Evaluation of response rate and disease control rate as potential predictors of overall survival in anthracycline-pretreated women receiving first-line chemotherapy for metastatic breast cancer (MBC)","volume":"29","author":"Liu","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2017.03.004_bib10","first-page":"6941","article-title":"Factors associated with the selection of first-line bevacizumab plus chemotherapy and clinical response in HER2-negative metastatic breast cancer: ONCOSUR AVALOX study","volume":"35","author":"Manso","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clbc.2017.03.004_bib11","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1200\/JCO.2008.21.6630","article-title":"Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer","volume":"27","author":"Gray","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2017.03.004_bib12","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.2147\/DDDT.S79563","article-title":"Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life","volume":"9","author":"Palumbo","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clbc.2017.03.004_bib13","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.2147\/DDDT.S89575","article-title":"Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients","volume":"9","author":"Fabi","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clbc.2017.03.004_bib14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3747\/co.20.1256","article-title":"Evaluation of the clinical benefits of nanoparticle albumin-bound paclitaxel in women with metastatic breast cancer in British Columbia","volume":"20","author":"Lohmann","year":"2013","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clbc.2017.03.004_bib15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3747\/co.20.1202","article-title":"Clinical outcomes of women with metastatic breast cancer treated with nab-paclitaxel: experience from a single academic cancer centre","volume":"20","author":"Dent","year":"2013","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clbc.2017.03.004_bib16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1470-2045(15)00542-2","article-title":"Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto\u2014GBG 69): a randomised, phase 3 trial","volume":"17","author":"Untch","year":"2016","journal-title":"Lancet Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820916303597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820916303597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:15:45Z","timestamp":1761513345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820916303597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S1526820916303597"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2017.03.004","relation":{},"ISSN":["1526-8209"],"issn-type":[{"type":"print","value":"1526-8209"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nab-Paclitaxel in Advanced HER2-negative Breast Cancer Patients: Efficacy and Safety Beyond Clinical Trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2017.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}